Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Neutral on Centene, Raises Price Target to $75

Credit Suisse analyst Jonathan Yong maintains Centene (NYSE:CNC) with a Neutral and raises the price target from $70 to $75.

byBenzinga Newsdesk

October 27, 2021

1 minute read

Credit Suisse analyst Jonathan Yong maintains Centene (NYSE:CNC) with a Neutral and raises the price target from $70 to $75.

GreenBox POS Announces Stablecoin Platform Spin-Off, Offers Special Dividend

By Anusuya Lahiri

Today, 12:09 PM

Financial technology company GreenBox POS (NASDAQ:GBOX) plans to implement a Special Dividend Series in two parts. The dividend is related to the…

GBOX

Evercore ISI Group Upgrades Park Hotels & Resorts to Outperform

By Benzinga Newsdesk

Today, 12:09 PM

Evercore ISI Group analyst Richard Hightower upgrades Park Hotels & Resorts (NYSE:PK) from In-Line to Outperform.

Goldman Sachs Maintains Buy on Schlumberger, Adds to Conviction List

By Benzinga Newsdesk

Today, 12:09 PM

Goldman Sachs analyst Neil Mehta maintains Schlumberger (NYSE:SLB) with a Buy, adds to Conviction List.

SLB

News

AstraZeneca Says Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes

By Michael Horton

Today, 12:09 PM

Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca's exenatide extended-release 2mg once weekly significantly reduced blood sugar—as measured by HbA1c—versus placebo in

AZN

Credit Suisse Maintains Neutral on Centene, Raises Price Target to $75

Related Posts

GreenBox POS Announces Stablecoin Platform Spin-Off, Offers Special Dividend

Evercore ISI Group Upgrades Park Hotels & Resorts to Outperform

Goldman Sachs Maintains Buy on Schlumberger, Adds to Conviction List

AstraZeneca Says Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes